Background: Chemotherapy induced mucositis is one of the deterring factors influencing adherence to cancer treatment. Sodium bicarbonate mouth wash was recently shown to increase patients’ compliance. However, the co...Background: Chemotherapy induced mucositis is one of the deterring factors influencing adherence to cancer treatment. Sodium bicarbonate mouth wash was recently shown to increase patients’ compliance. However, the cost implication of this strategy was never explored. Aim: This study is designed to explore the compounding of sodium bicarbonate 2% mouth wash from sodium bicarbonate powder USP and commercially procured intravenous solution, and to determine the estimated cost implication for patients using this strategy. Materials and Methods: Sodium bicarbonate 2% were compounded using commercially procured sterile intravenous 8.4% solution and powder USP, diluted and dissolved in sterile water for irrigation respectively. The estimated cost savings between the 2 methods were compared to each other as well as to savings from when used in preventing or in adjuvant therapy for chemotherapy induced mucositis. Ethical approval not required by UVA Institutional Review Board. Study conducted according to the International Standards of Good Practice. Result: We came up with a new recipe, sodium bicarbonate 2% mouth wash using commercially procured sterile liquid formulation. Due to shortage, we compounded with sodium bicarbonate powder USP. Using USP 795 regulation, we assigned 14 days beyond use date with refrigeration to these formulations. These formulations resulted in estimated cost savings of $3597.52 and $3686.56 respectively if patients were to be treated for chemotherapy induced mucositis for 21 days. When compared to commercially procured sterile liquid formulation, the use of powder USP, will lead to additional estimated 60 to 66.67% savings for patients. Conclusion: By using sodium bicarbonate powder or solution to compound a 2% mouth wash, we came up with a cheap product that could be used by patients in the moment in the hospital. We were also able to suggest ways that an estimated cost savings for patients undergoing cancer treatment that use this product can be computed.展开更多
目的:比较2%夫西地酸乳膏与2%莫匹罗星软膏治疗儿童细菌感染性皮肤病的疗效。方法:选取细菌感染性皮肤病患儿86例,按随机数字表法分为观察组和对照组,每组各43例。对照组患儿采用2%莫匹罗星软膏均匀涂抹患处,3次/d;观察组患儿采用2%夫...目的:比较2%夫西地酸乳膏与2%莫匹罗星软膏治疗儿童细菌感染性皮肤病的疗效。方法:选取细菌感染性皮肤病患儿86例,按随机数字表法分为观察组和对照组,每组各43例。对照组患儿采用2%莫匹罗星软膏均匀涂抹患处,3次/d;观察组患儿采用2%夫西地酸乳膏均匀涂抹患处,3次/d。两组患儿均治疗2周。比较治疗前后,两组患儿的湿疹面积和严重度指数(eczema area and severity index,EASI)评分及瘙痒评分,评价两组疗效,记录治疗过程中不良反应。结果:治疗后,两组患儿的EASI评分、瘙痒评分均较治疗前降低(P<0.05);且观察组患儿的EASI评分、瘙痒评分(2.44±0.76、0.94±0.11)与对照组(5.06±1.03、1.67±0.27)比较,差异有统计学意义(P<0.05)。治疗2周,观察组患儿的痊愈率(55.81%)显著高于对照组(30.23%),两组患儿比较差异有统计学意义(P<0.05)。两组患儿总有效率(97.67%、95.34%)比较,差异无统计学意义(P>0.05)。治疗期间,对照组患儿出现皮肤瘙痒1例、皮损局部灼热感1例;观察组患儿出现皮损局部灼热感1例。均未作特殊处理,自行缓解;未出现其他严重不良反应。结论:2%夫西地酸乳膏与2%莫匹罗星软膏治疗儿童细菌感染性皮肤病均安全有效,但2%夫西地酸乳膏总体疗效优于2%莫匹罗星软膏。展开更多
目的探讨2%葡萄糖酸氯己定皮肤消毒液在经外周静脉置入中心静脉导管(peripherally inserted central catheter,PICC)维护中的应用效果。方法 2013年5-9月便利选择南京大学医学院附属鼓楼医院肿瘤中心行PICC置管并在门诊进行导管维护的...目的探讨2%葡萄糖酸氯己定皮肤消毒液在经外周静脉置入中心静脉导管(peripherally inserted central catheter,PICC)维护中的应用效果。方法 2013年5-9月便利选择南京大学医学院附属鼓楼医院肿瘤中心行PICC置管并在门诊进行导管维护的肿瘤患者60例,按置管先后将其分为观察组和对照组各30例,对照组按照传统方法消毒,观察组采用2%葡萄糖酸氯己定局部皮肤消毒2次,比较两组患者皮肤细菌学培养结果、导管相关性感染的发生情况、PICC维护时间及耗材成本。结果两组患者均随访4周,均未出现导管相关性感染;PICC维护耗材成本,观察组为1.45元/(例·次),对照组为0.74元/(例·次),两组比较,差异有统计学意义(P<0.05);贴膜下皮肤细菌学培养结果及PICC导管维护时间观察组均少于或短于对照组,差异均有统计学意义(均P<0.01)。结论 2%葡萄糖酸氯己定皮肤消毒液应用于PICC维护,安全性高,效果好,且省时方便,有利于降低人力成本,提高临床工作效率。展开更多
文摘Background: Chemotherapy induced mucositis is one of the deterring factors influencing adherence to cancer treatment. Sodium bicarbonate mouth wash was recently shown to increase patients’ compliance. However, the cost implication of this strategy was never explored. Aim: This study is designed to explore the compounding of sodium bicarbonate 2% mouth wash from sodium bicarbonate powder USP and commercially procured intravenous solution, and to determine the estimated cost implication for patients using this strategy. Materials and Methods: Sodium bicarbonate 2% were compounded using commercially procured sterile intravenous 8.4% solution and powder USP, diluted and dissolved in sterile water for irrigation respectively. The estimated cost savings between the 2 methods were compared to each other as well as to savings from when used in preventing or in adjuvant therapy for chemotherapy induced mucositis. Ethical approval not required by UVA Institutional Review Board. Study conducted according to the International Standards of Good Practice. Result: We came up with a new recipe, sodium bicarbonate 2% mouth wash using commercially procured sterile liquid formulation. Due to shortage, we compounded with sodium bicarbonate powder USP. Using USP 795 regulation, we assigned 14 days beyond use date with refrigeration to these formulations. These formulations resulted in estimated cost savings of $3597.52 and $3686.56 respectively if patients were to be treated for chemotherapy induced mucositis for 21 days. When compared to commercially procured sterile liquid formulation, the use of powder USP, will lead to additional estimated 60 to 66.67% savings for patients. Conclusion: By using sodium bicarbonate powder or solution to compound a 2% mouth wash, we came up with a cheap product that could be used by patients in the moment in the hospital. We were also able to suggest ways that an estimated cost savings for patients undergoing cancer treatment that use this product can be computed.
文摘目的:比较2%夫西地酸乳膏与2%莫匹罗星软膏治疗儿童细菌感染性皮肤病的疗效。方法:选取细菌感染性皮肤病患儿86例,按随机数字表法分为观察组和对照组,每组各43例。对照组患儿采用2%莫匹罗星软膏均匀涂抹患处,3次/d;观察组患儿采用2%夫西地酸乳膏均匀涂抹患处,3次/d。两组患儿均治疗2周。比较治疗前后,两组患儿的湿疹面积和严重度指数(eczema area and severity index,EASI)评分及瘙痒评分,评价两组疗效,记录治疗过程中不良反应。结果:治疗后,两组患儿的EASI评分、瘙痒评分均较治疗前降低(P<0.05);且观察组患儿的EASI评分、瘙痒评分(2.44±0.76、0.94±0.11)与对照组(5.06±1.03、1.67±0.27)比较,差异有统计学意义(P<0.05)。治疗2周,观察组患儿的痊愈率(55.81%)显著高于对照组(30.23%),两组患儿比较差异有统计学意义(P<0.05)。两组患儿总有效率(97.67%、95.34%)比较,差异无统计学意义(P>0.05)。治疗期间,对照组患儿出现皮肤瘙痒1例、皮损局部灼热感1例;观察组患儿出现皮损局部灼热感1例。均未作特殊处理,自行缓解;未出现其他严重不良反应。结论:2%夫西地酸乳膏与2%莫匹罗星软膏治疗儿童细菌感染性皮肤病均安全有效,但2%夫西地酸乳膏总体疗效优于2%莫匹罗星软膏。
